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Realising early recognition of arthritis in times 
of increased telemedicine: the value of patient- 
reported swollen joints
Early diagnosis and management of patients with inflammatory 
arthritis (IA) are critical to improve long- term patient outcomes. 
Assessment of joint swelling at joint examination is the refer-
ence of IA identification; early access clinics are constructed 
to promote this early recognition. Due to the COVID-19 
pandemic, the face- to- face capacity of such services is severely 
reduced.1 This raises the concern of a major step backward 
after the important progress that has been made in the past 15 
years.1 Telemedicine has recently become rapidly implemented. 
Although probably a valuable alternative in the management of 
established rheumatoid arthritis (RA), there is also the fear that 
this might cause delay in the speed of diagnosis.2 A symptom 
that evidently raises suspicion for IA during remote evaluation is 
the presence of patient- reported swelling. This symptom is also 
included in triage tools.3 4
The accuracy of patient- reported swelling in comparison with 
joint examination has been extensively evaluated in established 
RA. Heterogeneous results are reported; correlation coefficients 
were higher when patient scored their swelling on mannequins 
(ρ: 0.31–0.67) than when determined with questions.5 Hypo-
thetically, the accuracy of patient- reported joint swelling for first 
recognition of IA is different than for flare detection in patients 
with established RA. To promote evidence- based care in the era 
of telemedicine, we determined the accuracy of patient- reported 
joint swelling for actual presence of IA in persons suspected of 
IA by general practitioners (GPs).
Data from two Dutch Early Arthritis Recognition Clinics were 
studied. These are screening clinics (1.5 lines setting) where GPs 
send patients in case of doubt on IA. At this clinic, patients were 
asked to mark the presence of swollen joints on a mannequin 
with 52 joints (42 joints were used for this analysis, see online 
supplemental text/figure S1). Subsequently, an experienced rheu-
matologist performed joint examination (see online supplemental 
text). Clinically apparent IA of ≥1 joint was the reference to 
calculate sensitivity, specificity, positive and negative likelihood 
ratios (LR+ and LR−) and positive and negative predictive value 
(PPV and NPV) on patient level. Pearson correlation coefficients 
(ρ) were determined. Predictive values depend on the prevalence 
of a disease in a population. Because the prevalence of IA in a 
1.5 lines setting will differ from a primary care setting, post- 
test probabilities of IA were estimated for two lower prior- test 
probabilities as example, namely 20% (estimated probability in 
patients GPs believe IA is likely) and 2% (prior- test probability 
with less preselection by GPs), using likelihood ratios and nomo-
grams (online supplemental figures S2 and S3).
A total of 1637 consecutive patients were studied. Patient 
characteristics are presented supplementary (online supple-
mental table S1). Median symptom duration was 13 weeks. 
Seventy- six per cent of patients marked ≥1 swollen joint at the 
mannequin. Forty- one per cent of patients had ≥1 swollen joint 
at examination by rheumatologists. ρ was 0.20 (patient level) to 
0.26 (joint level).
The sensitivity of patient- reported joint swelling was high, 
87%, indicating that the majority of patients with IA had 
marked swelling on the mannequin. However, the specificity 
was 31%, indicating that 69% of persons without IA had also 
done so (figure 1A). The LR+ was 1.25; the LR− 0.43. The PPV 
was 46%, and the NPV was 77% (figure 1B,C). Thus, the PPV 
increased hardly (from 41% to 46%), and the NPV somewhat 
increased (from 59% to 77%). Also in settings with prior- test 
probabilities of 20% and 2%, estimated PPVs and NPVs hardly 
increased (figure 1B,C).
Thus, patient- reported joint swelling had little value in distin-
guishing patients with and without IA, for different prior- test 
probabilities. Correlations identified in this population were 
lower than known for established RA. When evaluating ≥1 self- 
reported swollen and tender joints, similar results were obtained 
(online supplemental table S2). Together this suggests that evalu-
ation of patient- reported swelling is less valuable for early detec-
tion of IA than for flare detection in established RA.5 6
Thanks to the current pandemic, telemedicine has accelerated 
and will continue to grow in upcoming years.1 2 The challenge 
is to continue to work in an evidence- based manner. Although 
inaccurate when assessed alone, patient- reported swelling may 
be helpful when combined with other characteristics (either clin-
ical characteristics, such as published previously, and/or labora-
tory characteristics).3 4 7 8 Other innovative tools, for example, 
imaging modalities that do not require human- to- human 
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Figure 1 Test characteristics of patient- reported joint swelling (A) and 
predictive values (B and C), demonstrating the limited value of patient- 
reported joint swelling for detection of IA in three settings with different 
prior probabilities. (A) Sensitivity and specificity of patient- reported 
swollen joints with IA (joint swelling at physical examination as 
golden standard). (B) Prior probability on having IA of 41% (observed), 
20% (estimated) and 2% (estimated) with corresponding post- test 
probabilities on having IA, if patients indicate to have ≥1 swollen joints 
(PPV). (C) Prior- test probability of not having IA 59% (observed), 80% 
(estimated) and 98% (estimated) with the corresponding post- test 
probability on not having IA, if patients indicate no swollen joints (NPV). 
IA, inflammatory arthritis; NPV, negative predictive value; PPV, positive 
predictive value.
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contact, may also contribute to early identification of IA in a 
‘1.5m society’ with limited access to rheumatologists.
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